Cargando…
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832516/ https://www.ncbi.nlm.nih.gov/pubmed/31614473 http://dx.doi.org/10.3390/toxins11100586 |
_version_ | 1783466191327592448 |
---|---|
author | Chen, Chien-Hsu Tyagi, Pradeep Chuang, Yao-Chi |
author_facet | Chen, Chien-Hsu Tyagi, Pradeep Chuang, Yao-Chi |
author_sort | Chen, Chien-Hsu |
collection | PubMed |
description | Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. Here, we review the published evidence from animal models to clinical studies for inferring the mechanism of action underlying the therapeutic efficacy of BoNT in CP/CPPS. Animal studies demonstrated that BoNT-A, a potent inhibitor of neuroexocytosis, impacts the release of sensory neurotransmitters and inflammatory mediators. This pharmacological action of BoNT-A showed promise of relieving the pain of CP/CPPS in placebo-controlled and open-label BoNT-A and has the potential to serve as an adjunct treatment for achieving better treatment outcomes in CP/CPPS patients. |
format | Online Article Text |
id | pubmed-6832516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68325162019-11-25 Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome Chen, Chien-Hsu Tyagi, Pradeep Chuang, Yao-Chi Toxins (Basel) Review Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. Here, we review the published evidence from animal models to clinical studies for inferring the mechanism of action underlying the therapeutic efficacy of BoNT in CP/CPPS. Animal studies demonstrated that BoNT-A, a potent inhibitor of neuroexocytosis, impacts the release of sensory neurotransmitters and inflammatory mediators. This pharmacological action of BoNT-A showed promise of relieving the pain of CP/CPPS in placebo-controlled and open-label BoNT-A and has the potential to serve as an adjunct treatment for achieving better treatment outcomes in CP/CPPS patients. MDPI 2019-10-11 /pmc/articles/PMC6832516/ /pubmed/31614473 http://dx.doi.org/10.3390/toxins11100586 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chen, Chien-Hsu Tyagi, Pradeep Chuang, Yao-Chi Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
title | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
title_full | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
title_fullStr | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
title_full_unstemmed | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
title_short | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
title_sort | promise and the pharmacological mechanism of botulinum toxin a in chronic prostatitis syndrome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832516/ https://www.ncbi.nlm.nih.gov/pubmed/31614473 http://dx.doi.org/10.3390/toxins11100586 |
work_keys_str_mv | AT chenchienhsu promiseandthepharmacologicalmechanismofbotulinumtoxinainchronicprostatitissyndrome AT tyagipradeep promiseandthepharmacologicalmechanismofbotulinumtoxinainchronicprostatitissyndrome AT chuangyaochi promiseandthepharmacologicalmechanismofbotulinumtoxinainchronicprostatitissyndrome |